Key Factors in Choosing Specialty Patient Support
Specialty pharmaceutical manufacturers and provider teams are under more pressure than ever to get patients onto therapy quickly. But with barriers like prior authorization delays, copay challenges, or limited-distribution logistics, find a partner to support access that has the right processes and the right budget can be challenging.
This guide breaks down the factors that can glean insight into whether a patient support program will perform around the core functions manufacturers rely on most: prior authorization support, copay and reimbursement assistance, limited-distribution therapy support, and the patient access services infrastructure that ties it all together.
1. Adaptive Prior Authorization Support
Every hub should be able to handle prior authorizations. The differentiator is what happens when a submission gets denied. Here’s what to look for:
Documented turnaround times broken out by payer type, rather than a single blended average
A defined process for handling discrepancies or denials, including how fast an issue gets escalated to a human (and where this human sits in their org chart)
First-pass approval rates, since a high resubmission rate can signal a weak initial submission process rather than a challenging payer
Manufacturers should ask a prospective partner to walk through an actual denial scenario, start to finish, rather than describing their process in the abstract.
2. Copay and Reimbursement Assistance Designed to Reduce Abandonment
Copay and reimbursement assistance programs exist to remove the cost barrier between an approved therapy and a filled prescription. A well-run program should be measured on how many enrolled patients actually convert to fill instead of enrollment volume.
Key evaluation points:
How quickly a patient can be enrolled and activated after a prescription is written
Whether the program coordinates with foundation assistance and manufacturer copay cards without creating duplicate or conflicting patient touchpoints
How reimbursement issues are identified and resolved before they cause a lapse in therapy
3. Logistics as a Clinical Function
Limited-distribution therapies (LDTs) add a layer of complexity that general pharmacy support services aren't built to handle. But this architecture matters for operations and compliance alike.
What matters most:
Established relationships with the limited network of dispensing pharmacies for the therapy class in question
A coordination process between hub, pharmacy, and provider that doesn't require the patient to manage the handoffs themselves
Visibility into where a patient sits in the LDT pipeline at any given moment, not just a status update after the fact
4. Visibility Across the Entire Journey
Patient access services function best as connected infrastructure. Independent handoffs create complexity and risk drop off. A patient moving from benefit verification to prior authorization to copay enrollment to first fill should never experience that as four separate processes.
Evaluate whether a vendor can show:
A single view of where each patient stands across the full access journey
Defined escalation triggers when a patient stalls at any stage
Reporting that surfaces patterns across the patient population, not just individual case status
5. Software as a Tool, Not a Strategy
Technology matters, but it's frequently overweighted relative to the operational discipline behind it. The most sophisticated patient services software still depends on a well-run team to catch the exceptions that software alone can't resolve, because much of the friction in the healthcare access system is inherently manual.
Instead of asking how advanced a platform is, ask:
Where does the software actually reduce manual work, versus where does a person still have to step in?
How does the system flag and route exceptions, like an incomplete benefit verification response?
How does the platform integrate with the payer and provider workflows already in place, rather than requiring them to adapt to it?
6. PAP Coordination Across Multiple Support Layers
Patient assistance programs (PAPs) often operate alongside copay assistance, foundation support, and bridge programs. The strength of a support services partner is in how well these layers are coordinated, not in how many are offered.
Look for a partner that can:
Determine PAP eligibility early, before a coverage gap becomes a treatment delay
Manage the handoff between temporary bridge support and long-term assistance without a lapse
Track and report on PAP utilization as part of the broader access picture, not as a siloed program
7. Operational Discipline: The Factor Most Often Overlooked
Manufacturers frequently weigh disease-state experience and technology sophistication as a top priority, but in reality, neither reliably predicts performance. What does is operational discipline: the consistency with which a team executes benefit verification, prior authorization, and patient assistance workflows, and how quickly issues surface before they become patient-facing delays.
A support services partner that runs a disciplined, well-documented process in a therapeutic area they're new to will typically outperform one with deep disease-state familiarity but inconsistent execution.
Frequently Asked Questions
What is included in specialty patient support services? Specialty patient support services typically include benefit verification, prior authorization support, copay and reimbursement assistance, limited-distribution therapy coordination, and patient assistance program management, delivered through a connected hub infrastructure.
How do manufacturers evaluate a patient support services partner? The strongest evaluations focus on documented execution metrics such as prior authorization turnaround by payer type, escalation practices, and first-pass approval rates, rather than disease-state experience or technology features alone.
Is disease-state experience necessary for an effective hub partner? Not as a primary factor. Operational discipline and consistent execution across benefit verification, prior authorization, and patient assistance workflows are stronger predictors of program performance than direct disease-state background.
